Home » Stocks » CNTG

Centogene N.V. (CNTG)

Stock Price: $9.24 USD 0.13 (1.43%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $9.07 -0.17 (-1.82%) May 13, 4:11 PM
Market Cap 201.60M
Revenue (ttm) 156.56M
Net Income (ttm) -26.20M
Shares Out 22.12M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $9.24
Previous Close $9.11
Change ($) 0.13
Change (%) 1.43%
Day's Open 9.11
Day's Range 8.86 - 9.36
Day's Volume 43,613
52-Week Range 8.61 - 27.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson's disease (PD)

3 days ago - GlobeNewsWire

Centogene (CNTG) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

6 days ago - Zacks Investment Research

CENTOGENE's rare disease mutation database offers new features and previously unpublished variants CENTOGENE's rare disease mutation database offers new features and previously unpublished variants

1 week ago - GlobeNewsWire

Research leads to diagnosis and treatment options for rare disease patients Research leads to diagnosis and treatment options for rare disease patients

1 week ago - GlobeNewsWire

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Other stocks mentioned: BSX, HOLX, INGN, LH, OMI, XRAY
1 week ago - Zacks Investment Research

Delivers very strong financial results in unprecedented year Delivers very strong financial results in unprecedented year

4 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical a...

4 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinica...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that...

4 months ago - GlobeNewsWire

Seeking Alpha Transcripts | Healthcare Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript Dec. 16, 2020 2:58 PM ET | | About: Centogene N.V. (CNTG) by: SA Transcripts ...

4 months ago - Seeking Alpha

Shares of Centogene (NASDAQ:CNTG) remained unaffected in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 97.88% year over year to ($0.30), which mi...

4 months ago - Benzinga

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinica...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transform...

5 months ago - GlobeNewsWire

Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries Expanded Partnership Provide...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and ...

6 months ago - GlobeNewsWire

GENT, Belgium and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms r...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and BAARN, the Netherlands, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that tra...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clin...

7 months ago - GlobeNewsWire

Centogene N.V. (CNTG) CEO Arndt Rolfs on Q2 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases t...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clini...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clini...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced that it...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transfo...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and g...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 23, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical an...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases th...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced that its...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and SANTA MONICA, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network Inc, an i...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 02, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

10 months ago - GlobeNewsWire

Centogene (CNTG) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Shares of German genetic diagnosis company Centogene NV (NASDAQ: CNTG) were advancing strongly Monday.

10 months ago - Benzinga

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 29, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical an...

10 months ago - GlobeNewsWire

Cambridge, Mass. and ROSTOCK, Germany and BERLIN, June 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

10 months ago - GlobeNewsWire

Centogene N.V. (CNTG) CEO Arndt Rolfs on Q1 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and BERLIN and ROSTOCK, Germany, May 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., USA, ROSTOCK, Germany and BERLIN, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 08, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 06, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and...

1 year ago - GlobeNewsWire

About CNTG

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including tar... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 7, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CNTG
Full Company Profile

Financial Performance

In 2020, Centogene's revenue was 128.38 million, an increase of 163.18% compared to the previous year's 48.78 million. Losses were -21.49 million, 4.01% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Centogene stock is "Strong Buy." The 12-month stock price forecast is 20.84, which is an increase of 125.54% from the latest price.

Price Target
$20.84
(125.54% upside)
Analyst Consensus: Strong Buy